Quantitative pretreatment EEG predicts efficacy of ACTH therapy in infantile epileptic spasms syndrome

Clin Neurophysiol. 2022 Dec:144:83-90. doi: 10.1016/j.clinph.2022.10.004. Epub 2022 Oct 19.

Abstract

Objective: This study aimed to determine the correlation between outcomes following adrenocorticotrophic hormone (ACTH) therapy and measurements of relative power spectrum (rPS), weighted phase lag index (wPLI), and graph theoretical analysis on pretreatment electroencephalography (EEG) in infants with non-lesional infantile epileptic spasms syndrome (IESS).

Methods: Twenty-eight patients with non-lesional IESS were enrolled. Outcomes were classified based on seizure recurrence following ACTH therapy: seizure-free (F, n = 21) and seizure-recurrence (R, n = 7) groups. The rPS, wPLI, clustering coefficient, and betweenness centrality were calculated on pretreatment EEG and were statistically analyzed to determine the correlation with outcomes following ACTH therapy.

Results: The rPS value was significantly higher in the delta frequency band in group R than in group F (p < 0.001). The wPLI values were significantly higher in the delta, theta, and alpha frequency bands in group R than in group F (p = 0.007, <0.001, and <0.001, respectively). The clustering coefficient in the delta frequency band was significantly lower in group R than in group F (p < 0.001).

Conclusions: Our findings demonstrate the significant differences in power and functional connectivity between outcome groups.

Significance: This study may contribute to an early prediction of ACTH therapy outcomes and thus help in the development of appropriate treatment strategies.

Keywords: ACTH therapy; EEG quantitative analysis; Epileptic spasms; Infantile epileptic spasms syndrome; West syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenocorticotropic Hormone* / therapeutic use
  • Electroencephalography
  • Humans
  • Infant
  • Spasm
  • Spasms, Infantile* / diagnosis
  • Spasms, Infantile* / drug therapy
  • Syndrome
  • Treatment Outcome

Substances

  • Adrenocorticotropic Hormone